Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer

Breast cancer is the second most common cause of cancer-related deaths worldwide among women. Despite several therapeutic options, 15% of breast cancer patients succumb to the disease owing to tumor relapse and acquired therapy resistance. Particularly in triple-negative breast cancer (TNBC), develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Iskit, Sedef, Lieftink, Cor, Halonen, Pasi, Shahrabi, Aida, Possik, Patricia A., Beijersbergen, Roderick L., Peeper, Daniel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189992/
https://www.ncbi.nlm.nih.gov/pubmed/27374095
http://dx.doi.org/10.18632/oncotarget.10230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189992/
https://www.ncbi.nlm.nih.gov/pubmed/27374095
http://dx.doi.org/10.18632/oncotarget.10230

Ejemplares similares